Active Online Assessment of Patients Using New Oral Anticoagulants: Bleeding Risk, Compliance, and Coagulation Analysis

Abstract

Clinicians prescribing new oral anticoagulants (OACs; dabigatran, rivaroxaban, and apixaban) should be aware of the exclusion criteria related to bleeding risks defined in published clinical studies. At least a quarter of patients currently using warfarin have an exclusion criterion that may prevent easy transition to the new OACs. In the summary of product characteristics for dabigatran, as an example, the target populations appear generalized. Due to fixed dosing and predictable pharmacology, routine laboratory monitoring of new OACs is deemed unnecessary. Under special circumstances, however, understanding the extent of thrombin or factor (F) Xa inhibition may aid in evaluating compliance and handling emergency interventions, bleeding complications, or overdoses. Although commonly available global coagulation-time assessments (prothrombin time and activated partial thromboplastin time) are insensitive, they may assist clinical management by indicating a severe accumulation of OACs; moreover, a normal thrombin time (TT) excludes a thrombin-inhibitor effect. In particular circumstances, specific assays (diluted TT, Ecarin clotting time, anti-FIIa or anti-FXa activity) may quantify the anticoagulant effect, but therapeutic ranges for dose adjustment are not yet established. Laboratory results are also influenced by clinical situation: e.g. bleed (consumption of coagulation factors) versus postoperative state (activation of coagulation). Without specific antidotes and evidence-based treatment strategies, new OACs are clinically worrisome in patients with impaired renal or liver function. Postmarketing surveillance and recording of bleeding complications (ICD-10 D68.32) are therefore of major importance.

Do We Know All About Prevention of Venous Thromboembolism After Major Orthopedic Surgery?

“…еще одним тестом, линейно отображающим концен-трацию прямых ингибиторов тромбина в крови, является экариновое время [50]. Для прямых ин-гибиторов фактора Ха специфическим и наиболее чувствительным тестом является хромогенный метод определения анти-Xa активности, который позволяет точно определять уровень активности лекарственного средства [51,52].…”

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

“…2 6 7 Dabigatran was the first drug to be approved by the authorities for patients with non-valvular AF; however, the approval was followed by several concerns including case reports of serious bleedings 8 9 as well as concerns about poor adherence to therapy. 10 Consequently, the Food and Drug Administration (FDA) in the USA, and European Medicine Agency (EMA) brought a safety announcement of serious bleedings.…”

From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples

“…Nevertheless, under special circumstances, e.g. renal or hepatic dysfunction, acute bleeding complications or thrombosis, and emergency surgery, assessment of anticoagulation becomes necessary [3,4]. Coagulation laboratories must provide readily available (all hours) and practical tests for measurements of Dabi anticoagulation.…”